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Abstract 
Background: In mitochondrial diabetes, apoptosis of β‑cells caused by mitochondrial stress plays an important role 
in impaired insulin secretion. Several studies have reported that coenzyme Q10 (CoQ10) has therapeutic effects on 
mitochondrial diabetes, but no reports have examined the fundamental effectiveness or mechanism of CoQ10 in 
mitochondrial diabetes. We previously reported in a Japanese article that CoQ10 has protective effects on pancreatic 
β‑cells against mitochondrial stress using mouse pancreatic β‑cell line MIN6 and staurosporine (STS). Here, we report 
that CoQ10 protects MIN6 cells against apoptosis caused by STS and describe the more detailed apoptotic cascade.
Methods: Apoptosis of MIN6 cells was induced by 0.5 µM STS treatment for specific periods with or without 30 μM 
CoQ10. The apoptosis cascade in MIN6 cells was then investigated using WST‑8 assays, annexin‑V staining, western 
blotting, and DNA degradation analysis.
Results: Sixteen hours of 0.5 μM STS treatment led to 47% cell viability, but pretreatment with 30 μM CoQ10 resulted 
in significantly higher viability of 76% (P < 0.01). CoQ10 also prevented translocation of phosphatidylserine from the 
inner leaflet to the outer leaflet of the cell membrane. CoQ10 prevented cytochrome c release from mitochondria and 
activation of caspase‑3.
Conclusion: We concluded that CoQ10 protects pancreatic β‑cells through anti‑apoptotic effects against STS 
treatment.
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Background
Hyperglycemia occurs because of impaired insulin action 
in diabetes as a result of insulin resistance and impaired 
insulin secretion. In insulin resistance, although insulin 
is secreted, its effect decreases. Conversely, in impaired 
insulin secretion, insulin secretion itself decreases. Mito-
chondria are important for insulin secretion of pancreatic 
β-cells. Impaired insulin secretion occurs in mitochondrial 
diabetes, a hereditary disorder of mitochondrial functions 
[1]. Mitochondrial diabetes accounts for 1% of diabetes in 
Japan. Although insulin secretion depends on the function 
and quantity of pancreatic β-cells, these cells have a low 
proliferation ability, and their quantitative and qualitative 
decreases are strongly affected by apoptosis [2]. Apopto-
sis of β-cells is caused by oxidative stress, lipotoxity, and 
cytokines. Furthermore, it has been reported that pancreas 
β-cells decrease as a result of apoptosis in BHE/cdb rats, 
a model of mitochondrial diabetes [3]. These results sug-
gest that mitochondrial dysfunction and apoptosis have 
an important role in impaired insulin secretion. Other 
than insulin injection, treatments have not been estab-
lished for mitochondrial diabetes, although several studies 
have shown that coenzyme Q10 (CoQ10) has therapeutic 
effects on mitochondrial diabetes [4]. However, to the best 
of our knowledge, no reports have examined the funda-
mental effectiveness or mechanism of CoQ10 in mito-
chondrial diabetes. Reactive oxygen species produced by 
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has demonstrated the effectiveness of CoQ10 to treat a cen-
tral symptom of mitochondrial disease [6]. The antioxidant 
and ATP supplying effects of CoQ10 may protect central 
nerves [7]. Therefore, the mechanism of CoQ10 treatment 
in mitochondrial diabetes might be protective effects from 
apoptosis of pancreatic β-cells. We previously reported in a 
Japanese article that CoQ10 has protective effects on pan-
creatic β-cells against mitochondrial stress using mouse 
pancreatic β-cell line MIN6 and staurosporine (STS), a 
strong inducer of apoptosis and mitochondrial stress by 
producing reactive oxygen species [8, 9]. Here, we report 
that CoQ10 protects MIN6 cells against apoptosis caused 
by STS and describe the apoptotic cascade.
Methods
Materials
Mouse insulinoma cell line MIN6 was kind gift from Dr. 
Makoto Shigeto (Division of Diabetes and Endocrinology 
Department of Medicine Kawasaki Medical School), Kohei 
Kaku (Division of Diabetes and Endocrinology Depart-
ment of Internal Medicine Kawasaki Medical School), 
and Jun-ichi Miyazaki (Division of Stem Cell Regulation 
Research, Osaka University Graduate School of Medicine). 
Fetal bovine serum (FBS) was obtained from Thermo 
Fisher Scientific, Inc. (Kanagawa, Japan). Phosphate buff-
ered saline (PBS), Dulbecco’s modified Eagle’s medium 
(DMEM), penicillin, and streptomycin were obtained from 
Sigma-Aldrich, Inc. (St. Louis, MO). CoQ10 (oxidized 
form) was obtained from Yokohama Oils & Fats Industry 
(Kanagawa, Japan). Z-VAD-FMK (carbobenzoxy-valyl-
alanyl-aspartyl-[O-methyl]-fluoromethylketone) was 
obtained from Peptide Institute, Inc. (Osaka, Japan). STS 
and polyacrylamide gels were obtained from Wako Pure 
Chemical Industries (Osaka, Japan). A protease inhibitor 
cocktail was obtained from BioVision, Inc. (Milpitas, CA). 
Tris/Glycine/SDS electrophoresis buffer was obtained 
from Bio-Rad Laboratories, Inc. (Hercules, CA). West-
ern Blotting Detection Reagent was obtained from GE 
Healthcare (Tokyo, Japan). Polyvinylidene fluoride (PVDF) 
microporous membranes were obtained from Merck Mil-
lipore (Billerica, MA). Cell lysis buffer, an anti-β-actin 
antibody, anti-rabbit IgG, and annexin V assay kit were 
obtained from MBLCo., Ltd. (Aichi, Japan). An anti-cas-
pase-3 antibody was obtained from Cell Signaling Tech-
nology (Tokyo, Japan). A cytochrome c releasing apoptosis 
assay kit was obtained from Funakoshi Co., Ltd. (Tokyo, 
Japan). An apoptotic DNA ladder kit was obtained from 
Roche Diagnostics (Tokyo, Japan). Cell Counting Kit-8 was 
obtained from Dojindo Laboratories (Kumamoto, Japan).
Cell culture
MIN6 cells were cultured in 60 ml flasks, 96-well plates, or 
on glass coverslips in DMEM (high-glucose; 4.5 g/l) with 
15% FBS, 75  μg/ml penicillin, and 50  μg/ml streptomy-
cin at 37 °C in a humidified atmosphere with 5%  CO2. At 
80% confluence, the cells were divided into four groups: 
CoQ10, Z-VAD, STS, and control. The CoQ10 group was 
treated with 30  μM CoQ10 for 4  h before induction of 
apoptosis. Z-VAD-FMK is a pan-caspase inhibitor and 
anti-apoptotic agent. The Z-VAD group was treated with 
30 μM Z-VAD-FMK for 1 h before induction of apopto-
sis. STS and control groups were not pre-treated. Except 
for the control group, each group was treated with 0.5 μM 
STS for the specified periods to induce apoptosis.
WST‑8 assay
Cell viability was compared among the four groups after 
apoptotic stimulation using Cell Counting Kit-8 that deter-
mines cell viability through reduction of s water-soluble 
tetrazolium salt, WST-8. WST-8 is reduced by dehydroge-
nases in cells to produce a yellow formazan dye. The amount 
of formazan dye generated by the activities of dehydroge-
nases in cells is directly proportional to the number of living 
cells. Except for the control group, MIN6 cells were treated 
in 96-well plates (100 μl medium per well) with 0.5 μM STS 
for 16 h. Then, 10 μl Cell Counting Kit-8 solution was added 
to each well, followed by incubation for 2 h. The number of 
living cells was determined by absorbance at 450 nm using 
fluorescence microplate reader. Several experiments were 
performed, and average values were calculated.
Annexin‑V staining
At the early stage of apoptosis, cells lose their phospholipid 
membrane asymmetry and expose phosphatidylserine (PS) 
at the cell surface. This process can be monitored using 
annexin-V, a  Ca2+-dependent, phospholipid-binding pro-
tein with high affinity for PS, which is useful for identifying 
apoptotic cells with exposed PS. For annexin-V staining, 
MIN6 cells were cultured on glass coverslips. After 6 h of 
treatment with STS, cells were washed with PBS and then 
stained with green fluorescent protein-labeled annexin-
V for 5 min while protected from light, according to the 
manufacturer’s protocol. The cells were then washed with 
PBS and treated with methanol for 10 min. The methanol 
was removed, and propidium iodide (PI) was added, a red 
fluorescent nuclear counterstain. Samples were observed 
under a fluorescence microscope. Methanol-treated sam-
ples (all cells) were stained with PI (red), whereas early 
apoptotic cells were stained with annexin-V (green) and 
PI. We counted respectively 140, 113, 208 and 235 cells in 
Control, STS, CoQ10 and Z-VAD group. Thus, we were 
able to calculate the ratio of early apoptotic cells.
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SDS‑polyacrylamide gel electrophoresis (PAGE) 
and western blot analysis
To detect activation of caspase-3 and cytochrome c release 
from mitochondria after treatment with STS, cells were 
washed and then lysed in cell lysis buffer containing a pro-
tease inhibitor cocktail. The cell lysates (10 µg protein per 
sample) were then separated by 12.5% SDS-PAGE and 
electrotransferred onto a PVDF transfer membrane. Mem-
branes were blocked with Tris-buffered saline containing 
with 0.05% Tween 20 and 5% nonfat dried milk and then 
incubated with primary antibodies for 1  h at room tem-
perature. Primary antibodies were against caspase-3 (1:1000 
dilution), cytochrome c (1:200 dilution), and β-actin (1:1000 
dilution). The membrane was then incubated with second-
ary antibodies for appropriate times (30–60 min). Specific 
proteins were visualized by the enhanced chemilumines-
cence method using western blotting detection reagent.
DNA degradation analysis
After 14 h of treatment with STS, isolation of DNA from 
cells of each group was performed according to a stand-
ard procedure using a commercially available apoptotic 
DNA ladder kit. DNA fragmentation analysis was per-
formed using a 1.5% agarose gel.
Statistical analysis
Data are expressed as the mean ± standard deviation. 
Comparisons of individual treatments in WST-8 assays 
were conducted using the Games-Howell post hoc test 
following one-way analysis of variance. Comparisons 
of individual treatments in annexin-V analysis were 
conducted using the Chi square test. P < 0.05 was consid-
ered as statistically significant.
Results
Comparing of cell viability
We first examined cell viability after STS treatment using 
WST-8 assays (Fig. 1). After 16 h of STS treatment, the 
STS group had 47% cell viability, but the CoQ10 group 
had significantly higher viability of 76% (P < 0.01 vs. STS 
group). The Z-VAD group had 60% cell viability (P < 0.01 
vs. STS group). These results indicate that CoQ10 has a 
protective effect on MIN-6 cells against STS treatment, 
and CoQ10 has the same or a stronger protective effect 
than Z-VAD-FMK.
DNA fragmentation
Next, we examined DNA fragmentation to determine 
whether cell death was caused by apoptosis (Fig. 2). Elec-
trophoresis of genomic DNA from MIN6 cells treated 
with STS for 14  h revealed the characteristic laddering 
pattern, indicating that MIN6 cell death was caused by 
apoptosis. However, DNA fragmentation was inhibited 
by CoQ10 and Z-VAD, suggesting that CoQ10 had a pro-

























Fig. 1 Comparison of cell viability among the four groups after 
apoptotic stimulation using WST‑8 assays. Control, MIN6 cells cultured 
in regular medium; STS, cells exposed to STS (0.5 µM for 16 h); CoQ10, 
cells pretreated with CoQ10 (30 µM for 4 h) and then exposed to 
STS (0.5 µM for 16 h); Z‑VAD, cells pretreated with Z‑VAD‑FMK (30 µM 
for 1 h) and then exposed to STS (0.5 µM for 16 h). Comparisons of 
individual groups were conducted using the Games‑Howell post hoc 






Fig. 2 CoQ10 protects MIN6 cells from apoptosis induced by STS 
treatment. Control, MIN6 cells cultured in regular medium; STS, cells 
exposed to STS (0.5 µM for 14 h); CoQ10, cells pretreated with CoQ10 
(30 µM for 4 h) and then exposed to STS (0.5 µM for 14 h); Z‑VAD, cells 
pretreated with Z‑VAD‑FMK (30 µM for 1 h) and then exposed to STS 
(0.5 µM for 14 h). DNA fragmentation was observed in the STS group, 
which was inhibited by CoQ10 and Z‑VAD
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Annexin‑V analysis
Next, we investigated the detailed apoptosis cascade. 
During apoptosis, characteristic biochemical changes 
are observed. Translocation of PS from the inner leaf-
let to the outer leaflet of the cell membrane is one of the 
characteristic biochemical changes in the early stage of 
apoptosis. We investigated exposure of PS using annexin-
V staining together with PI staining. After 6  h of STS 
treatment, 15% of cells in the STS group were positive 
for annexin-V. Conversely, only 1% of cells in the CoQ10 
group and 3% of cells in the Z-VAD group were positive 
for annexin-V (Fig. 3).
Release of cytochrome c
Cytochrome c release from mitochondria is a central 
event in apoptotic signaling. Cytochrome c usually exists 
between mitochondrial inner and outer membranes, 
but it is released to the cytoplasm by apoptotic stimula-
tion. Then, cytochrome c together with Apaf-1 activate 
caspase-9, leading to the apoptotic caspase cascade. We 
investigated the release of cytochrome c from mitochon-
dria by western blotting using a commercially available 
kit. After 14  h of STS treatment, cytochrome c release 
was increased in the STS group. However, cytochrome c 
release in the other groups was lower than that in the STS 
group (Fig. 4). These results indicated that cytochrome c 
was released into the cytoplasm from mitochondria by 
STS treatment.
Caspase‑3
We also investigated activation of caspase-3 by western 
blotting. After 12 h of STS treatment, cleaved caspase-3, 
which is the activated form of caspase-3, was strongly 
detected in the STS group. Conversely, activation of 
caspase-3 was inhibited in CoQ10 and Z-VAD groups 
(Fig. 5).
Discussion
In the pathophysiology of diabetes including mitochon-
drial diabetes, apoptosis of β-cells plays important roles in 
impaired insulin secretion. Although the detailed funda-
mental mechanism of CoQ10 in mitochondrial diabetes is 
unknown, therapeutic effects of CoQ10 on mitochondrial 
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Fig. 3 CoQ10 prevents early events of apoptosis induced by STS treatment. Control, MIN6 cells cultured in regular medium; STS, cells exposed 
to STS (0.5 µM for 6 h); CoQ10, cells pretreated with CoQ10 (30 µM for 4 h) and then exposed to STS (0.5 µM for 6 h); Z‑VAD, cells pretreated with 
Z‑VAD‑FMK (30 µM for 1 h) and then exposed to STS (0.5 µM for 6 h). Annexin‑V‑positive cells indicate exposure of PS at the cell surface, the early 
stage of apoptosis (green). Cells treated with methanol were PI positive (scale bar is 100 µm)
Fig. 4 CoQ10 suppresses cytochrome c release from mitochondria. 
Control, MIN6 cells cultured in regular medium; STS, cells exposed to 
STS (0.5 µM for 14 h); CoQ10, cells pretreated with CoQ10 (30 µM for 
4 h) and then exposed to STS (0.5 µM for 14 h); Z‑VAD, cells pretreated 
with Z‑VAD‑FMK (30 µM for 1 h) and then exposed to STS (0.5 µM for 
14 h). In the STS group, cytochrome c release was high. This change 
was suppressed by CoQ10
Page 5 of 6Sumi et al. Diabetol Metab Syndr  (2018) 10:47 
diabetes have been reported in several studies [4]. We 
hypothesized that CoQ10 has protective effects against 
apoptosis in pancreatic β-cells. In this study, we induced 
apoptosis of MIN6 cells using STS, a mitochondrial stress 
agent [9]. In WST-8 assays, 0.5 µM STS treatment for 16 h 
induced the death of about half of the cells. Although cell 
death might be caused by both apoptosis and necrosis, 
we showed translocation of PS from the inner leaflet to 
the outer leaflet of the MIN6 cell membrane, release of 
cytochrome c from mitochondria, activation of caspase-3, 
and DNA fragmentation of MIN6 cells. Therefore, MIN6 
cell death induced by STS treatment was caused by apop-
tosis in this study. Based on these results, β-cells were pro-
tected by CoQ10 from apoptosis caused by STS treatment. 
In addition, this protective effect was equivalent to that 
of Z-VAD-FMK, an anti-apoptotic agent, suggesting that 
CoQ10 may be an effective anti-apoptotic agent. The fun-
damental effectiveness or mechanism of CoQ10 in mito-
chondrial diabetes have not been reported. However, the 
clinical effectiveness of CoQ10 against a central symptom 
of mitochondrial disease has been reported [6]. The mech-
anism is an antioxidant action and stimulates ATP supply 
from mitochondria [7]. In our study, CoQ10 had an anti-
apoptotic action in β-cells. We believe that the protective 
mechanism of CoQ10 is a direct effect on mitochondria 
through ATP supply, but elucidation of the detailed mecha-
nism is needed in the future. In mitochondrial diabetes, 
a hereditary disorder of mitochondrial functions causes 
impaired insulin secretion [1]. Conversely, in type-2 diabe-
tes, mitochondrial dysfunction caused by various kinds of 
stress, such as oxidative stress, plays important roles in the 
pathological progression [10]. Hodgson et al. [11] reported 
that CoQ10 treatment improves blood pressure and glyce-
mic control in type-2 diabetes patients. This finding sug-
gests that CoQ10 may have protective effects on pancreatic 
β-cells against mitochondrial stress in the clinic. In Japan, 
CoQ10 as a ubiquinone is applicable to insurance for heart 
failure, but not diabetes. However, CoQ10 is already gen-
erally used as a supplement. Therefore, if evidence that 
CoQ10 has effective effects on mitochondrial or type-2 dia-
betes accumulates, CoQ10 may be adopted clinically.
There are limitations in our study. First, STS treat-
ment is non-physiological stimulation. Further studies 
are needed to clarify whether CoQ10 has protective 
effects against apoptosis induced by physiological 
stimulation. Second, we only investigated MIN6 cells. 
Experiments using an animal model are necessary to 
examine the clinical effectiveness of CoQ10. However, 
we revealed a part of the underlying mechanism of 
CoQ10 in protection of pancreatic β-cells from apop-
tosis caused by mitochondrial stress. Elucidation of the 
more detailed mechanism may facilitate clinical appli-
cation of CoQ10.
Conclusion
CoQ10 protects pancreatic β-cells through anti-apop-
totic effects against STS treatment.
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Fig. 5 CoQ10 suppresses activation of caspase‑3 induced by STS 
treatment. Control, MIN6 cells cultured in regular medium; STS, cells 
exposed to STS (0.5 µM for 12 h); CoQ10, cells pretreated with CoQ10 
(30 µM for 4 h) and then exposed to STS (0.5 µM for 12 h); Z‑VAD, cells 
pretreated with Z‑VAD‑FMK (30 µM for 1 h) and then exposed to STS 
(0.5 µM for 12 h). Cleaved caspase‑3 is the active form of caspase‑3. 
STS induced activation of caspase‑3, but CoQ10 suppressed this 
activation
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